Because the loss-of-function mutations of LKB1 and the gain-of-function mutations of K-RAS are two major lung cancer-driven genes, we further evaluated whether FBXO22 expression predicts prognosis related to the status of LKB1and K-RAS in lung adenocarcinoma patients. This evidence concerns the gene KRAS and lung carcinoma.